Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases. Ono will work alongside Mediar to utilise its fibrosis-focused discovery platform, expertise in myofibroblast development, and knowledge of fibrosis pathways. This partnership gives Ono the exclusive option to license worldwide rights to develop and commercialise these therapeutic programmes. “Mediar has established deep scientific expertise in fibrosis and antibody discovery. Similarly, MTX-463 targets the WNT1-inducible signalling pathway protein-1 (WISP1), a crucial factor in fibrosis development.